Clinical trials: Metformin
Healthy
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and…
- Trial name
- NCT02266472
- Testing
- metformin, empagliflozin/metformin, empagliflozin
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Metabolic Syndrome
Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular…
- Trial name
- NCT03355469
- Testing
- Metformin, Low Intensity Exercise, High Intensity Exercise
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rutgers University
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble Insulin Analogue Combination [SIAC], insulin degludec/insulin aspart) formulations with each other and with biphasic insulin aspart 30…
- Trial name
- NCT00613951
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart, metformin
- Where
- 31 sites in Finland, France and 3 more
- Volunteers
- 182 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons…
- Trial name
- NCT01077323
- Testing
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Where
- United States
- Volunteers
- 363,766 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2…
- Trial name
- LIRA-Ramadan™ (NCT01917656)
- Testing
- liraglutide, metformin, sulphonylurea
- Where
- 41 sites in Algeria, India and 5 more
- Volunteers
- 343 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic…
- Trial name
- NCT00641056
- Testing
- Exenatide Once Weekly, Insulin Glargine
- Where
- 75 sites in United States, Australia and 14 more
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-X (NCT00707031)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 639 people
- Sponsor
- Sanofi
Obesity, Hypertension
The Effects of Metformin on Blood Vessel Structure and Function
The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on the blood vessels of individuals with the Metabolic Syndrome (MeS).
- Conditions
- Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
- Trial name
- NCT00105066
- Testing
- Metformin
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Institute on Aging (NIA)
Non-Insulin-Dependent Diabetes Mellitus
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients.
- Trial name
- NCT00318656
- Testing
- rosiglitazone-metformin fixed dose combination, metformin + glimepiride
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information
- Trial name
- AVANDAMETPMS (NCT01294553)
- Testing
- Administration of rosiglitazone/metformin
- Volunteers
- 717 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Dyslipidemias
Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.
- Trial name
- NCT00770653
- Testing
- Pioglitazone and Metformin, Glimepiride and Metformin
- Where
- 64 sites in Germany
- Volunteers
- 305 people
- Sponsor
- Takeda
Type 2 Diabetes
Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone
The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.
- Trial name
- Synergy104 (NCT00995345)
- Testing
- KRP-104
- Where
- 45 sites in United States, Argentina and 5 more
- Volunteers
- 403 people
- Sponsor
- ActivX Biosciences, Inc.
Type 2 Diabetes
Saxagliptin Triple Oral Therapy
The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes…
- Trial name
- NCT01128153
- Testing
- Saxagliptin
- Where
- 33 sites in Australia, Canada and 4 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2 Diabetes
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT01485614
- Testing
- Sitagliptin, Metformin, Glycemic Rescue 1
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
Aging
Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)
The purpose of this study is to determine whether a commonly prescribed drug, metformin, can enhance the benefits seen during resistance exercise such as increased muscle mass and strength.
- Trial name
- NCT02308228
- Testing
- Progressive Resistance Training, Metformin
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Philip Kern
Depression, Insulin Resistance
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
Insulin resistance, a primary component of the metabolic syndrome, is an escalating phenomenon in the United States, and confers an increased risk of depression and mood disorder, particularly in women.
- Conditions
- Depression, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT02069379
- Testing
- Metformin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Diabetes
Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after 6 weeks of treatment: Objective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on hepatic…
- Trial name
- NCT00820573
- Testing
- Sitagliptin, Metformin, Sitagliptin + Metformin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and administered twice daily (BID) on circulating glucose…
- Trial name
- NCT01804842
- Testing
- Met DR
- Volunteers
- 26 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with…
- Trial name
- NCT01084005
- Testing
- linagliptin
- Where
- 34 sites in Australia, Canada and 3 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim